Splenic 18F-FDG uptake on baseline PET/CT is associated with oncological outcomes and tumor immune state in uterine cervical cancer.
暂无分享,去创建一个
O. De Wever | K. K. van de Vijver | F. Amant | H. Denys | P. D. De Visschere | K. Vandecasteele | A. Makar | L. Lippens | P. Tummers | K. De Man | E. D. De Jaeghere | E. Naert | F. Laloo | J. van Dorpe | M. V. van Bockstal
[1] O. De Wever,et al. Fibroblasts Fuel Immune Escape in the Tumor Microenvironment. , 2019, Trends in cancer.
[2] K. Shim,et al. Diffuse splenic FDG uptake is predictive of clinical outcomes in patients with rectal cancer , 2019, Scientific Reports.
[3] B. Lindsey,et al. Using the Spleen as an In Vivo Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with α-PD-L1 , 2018, Sarcoma.
[4] Ji-In Bang,et al. Clinical utility of FDG uptake within reticuloendothelial system on F-18 FDG PET/CT for prediction of tumor recurrence in breast cancer , 2018, PloS one.
[5] M. Mauro,et al. The Significance of Leukocytosis in Malignancies: A Novel Paradigm Between Leukocytosis, G-CSF, Myeloid-Derived Suppressor Cells and Prognosis , 2018, Blood.
[6] W. De Neve,et al. Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates , 2018, BMC Cancer.
[7] C. Houser,et al. Use of Functional Magnetic Resonance Imaging in Cervical Cancer Patients With Incomplete Response on Positron Emission Tomography/Computed Tomography After Image-Based High-Dose-Rate Brachytherapy. , 2018, International journal of radiation oncology, biology, physics.
[8] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[9] C. Moon,et al. Prognostic value of diffuse splenic FDG uptake on PET/CT in patients with gastric cancer , 2018, PloS one.
[10] Jedd D. Wolchok,et al. Cancer immunotherapy using checkpoint blockade , 2018, Science.
[11] S. Fanti,et al. Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer , 2018, International Journal of Gynecologic Cancer.
[12] Jieying Zhang,et al. Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of PET-CT , 2018, Theranostics.
[13] Steve Y. Cho,et al. Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better? , 2018, Nuclear Medicine and Molecular Imaging.
[14] F. Landoni,et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] G. Roman-Jimenez,et al. Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[16] Jae Kwan Lee,et al. Prognostic value of total lesion glycolysis measured by 18F-FDG PET/CT in patients with locally advanced cervical cancer , 2016, Nuclear medicine communications.
[17] D. Milne,et al. Spleen to liver ratio (SLR): Novel PET imaging biomarker for prediction of overall survival after ipilimumab and anti-PD1 in patients with metastatic melanoma. , 2016 .
[18] John O. Prior,et al. [18F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy , 2016, Radiation Oncology.
[19] P. Høilund-Carlsen,et al. FDG PET/CT in cancer: comparison of actual use with literature-based recommendations , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[20] J. Min,et al. Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. , 2015, JACC. Cardiovascular imaging.
[21] J. Java,et al. Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation. , 2014, Gynecologic oncology.
[22] Dong Soo Lee,et al. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Head and Neck Cancer: A Systematic Review and Meta-Analysis , 2014, The Journal of Nuclear Medicine.
[23] H. Kim,et al. Splenic FDG uptake predicts poor prognosis in patients with unresectable cholangiocarcinoma , 2013, Nuklearmedizin.
[24] M. Pittet,et al. The spleen in local and systemic regulation of immunity. , 2013, Immunity.
[25] L. Delrue,et al. Completion Surgery After Intensity-Modulated Arc Therapy in the Treatment of Locally Advanced Cervical Cancer: Feasibility, Surgical Outcome, and Oncologic Results , 2013, International Journal of Gynecologic Cancer.
[26] Kyoungjune Pak,et al. Impact of cytokines on diffuse splenic 18F-fluorodeoxyglucose uptake during positron emission tomography/computed tomography , 2013, Nuclear medicine communications.
[27] P. Grigsby,et al. FDG-PET-based prognostic nomograms for locally advanced cervical cancer. , 2012, Gynecologic oncology.
[28] C Marini,et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] J. Ochando,et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. , 2012, Cell reports.
[30] H. Chung,et al. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. , 2011, Gynecologic oncology.
[31] Wolfgang A Weber,et al. Quantitative analysis of PET studies. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[32] T. Yen,et al. Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. , 2009, International journal of radiation oncology, biology, physics.
[33] D. Alberts,et al. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] P. Grigsby,et al. The standardized uptake value for F‐18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival , 2007, Cancer.
[35] P. Grigsby,et al. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. , 2006, Gynecologic oncology.
[36] P. Grigsby,et al. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. , 2002, International journal of radiation oncology, biology, physics.
[37] Y Narita,et al. Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging. , 1999, International journal of radiation oncology, biology, physics.
[38] G. Thomas. Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy. , 1999, The New England journal of medicine.
[39] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[40] L. Azoulay,et al. Altered hepatic metabolic activity in patients with hepatic steatosis on FDG PET/CT. , 2011, AJR. American journal of roentgenology.